Healio Minute Podcast, Neurology Edition: Top Headlines - Week of May 23, 2023
Click Here to Manage Email Alerts
In this edition, FDA approves supplemental new drug application for Rexulti, early amyloid PET provides high diagnostic confidence, Leqembi reduced biomarkers of Alzheimer’s and more.
Read the full coverage here:
FDA approves supplemental new drug application for Rexulti to treat Alzheimer's agitation
Early amyloid PET provides high diagnostic confidence for adults with cognitive impairment
Leqembi reduced biomarkers of Alzheimer’s, slowed cognitive decline at 18 months
FDA grants 510(k) clearance for self-directed EEG headset
Oral Bruton’s tyrosine kinase inhibitor reduced brain lesions in phase 2 MS trial
References:
Altomare D, et al. JAMA Neurol. 2023;doi:10.1001/jamaneurol.2023.0997.
Van Dyck CH, et al. A study to confirm safety and efficacy of lecanemab in participants with early Alzheimer’s disease (Clarity AD). Presented at: American Academy of Neurology annual meeting; April 22-27, 2023; Boston.
Collapse
Read more about
Click Here to Manage Email Alerts
